BIOBEHAVIORAL APPROACHES TO HYPERTENSION

该项目将针对特定的人群，中等收入的个人 到严重的高血压，其疾病需要至少两种药物， 利尿剂和交感神经阻滞剂，以管理。我们将确定是否 两种行为疗法或非药物疗法之一，缩写 渐进式松弛或热生物反馈可以取代 高血压治疗中的第二阶段药物或交感神经药物 在一项对照试验中。此外，我们将比较两个后续行动 一年以上的维护程序，每月的助推器课程 行为治疗与标准医疗相比，看看前者是否 导致相对于后者更好的维护。更具体地说，100 患有中度到重度原发性高血压的人会， 在经历了广泛的生理、生化、心理和 心理生理评估，被随机分配到接受 简称渐进式放松或热生物反馈。每个子集 50将被进一步细分，以便其中一半将获得行为 在服用两种药物的同时接受治疗，而另一半将接受 第二阶段用药后停止治疗。从 治疗前评估小组我们将制定一个方案来预测谁 对行为治疗反应积极，而谁不反应。广泛性 生化评估将使我们能够通过 这些行为疗法是有效的。

This project will target a specific population, individuals with moderate to severe essential hypertension whose disease requires at least two drugs, diuretics and sympathetic blocking agents, to manage. We will determine if either of two behavioral, or non-pharmacological, treatments, abbreviated progressive relaxation or thermal biofeedback, can be substituted for the second stage, or sympatholytic, drug in the management of the hypertension in a controlled trial. Furthermore, we will compare two follow-up maintenance procedures over one year, monthly booster sessions of behavioral treatment versus standard medical care, to see if the former leads to improved maintenance vis-a-vis the latter. More specifically, l00 individuals suffering from moderate to severe essential hypertension will, after an extensive physical, biochemical, psychological and psychophysiological assessment, be randomly assigned to receive either abbreviated progressive relaxation or thermal biofeedback. Each sub-set of 50 will be further sub-divided such that half will receive behavioral treatment while on two drugs while the other half will receive the treatment after the second stage medication is discontinued. From the pre-treatment assessment battery we will develop a scheme to predict who responds positively to behavioral treatment and who does not. Extensive biochemical assessments will allow us to understand the mechanism through which the behavioral treatments work.